GILD · 8-K · 20260804PR000028

Operating Expense Trends

GILEAD SCIENCES, INC. · 2026-08-04 · Importance 72 · Surprise 74 · No source text

GAAP R&D expense increased 18% year over year to $1.764 billion from $1.491 billion, primarily due to integration costs and other acquisition-related expenses, partly offset by lower oncology clinical study activity. Non-GAAP R&D expense declined 1% to $1.429 billion, reflecting the lower oncology clinical study activity. GAAP SG&A expense increased 41% to $1.921 billion from $1.365 billion because of acquisition integration costs and higher HIV promotional activity. Non-GAAP SG&A expense increased 12% to $1.521 billion, driven primarily by higher HIV promotional activity.

Key facts

• Intangible assets, net decreased from $16,978 million as of December 31, 2025 to $14,032 million as of June 30, 2026 source
• SG&A expenses in Q2 2026: $1,921 million compared to $1,365 million in Q2 2025 source
• Non-GAAP SG&A expenses in Q2 2026: $1,521 million compared to $1,358 million in Q2 2025 source
• R&D expenses in Q2 2026: $1,764 million compared to $1,491 million in Q2 2025 source
• Non-GAAP R&D expenses in Q2 2026: $1,429 million compared to $1,450 million in Q2 2025 source

Impact estimates